Details
Stereochemistry | RACEMIC |
Molecular Formula | C10H14O3 |
Molecular Weight | 182.2164 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(OCC(O)CO)C=CC=C1
InChI
InChIKey=JWDYCNIAQWPBHD-UHFFFAOYSA-N
InChI=1S/C10H14O3/c1-8-4-2-3-5-10(8)13-7-9(12)6-11/h2-5,9,11-12H,6-7H2,1H3
Molecular Formula | C10H14O3 |
Molecular Weight | 182.2164 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.medindia.net/doctors/drug_information/mephenesin.htm | https://www.ncbi.nlm.nih.gov/pubmed/18886031
Curator's Comment: description was created based on several sources, including:
http://www.medindia.net/doctors/drug_information/mephenesin.htm | https://www.ncbi.nlm.nih.gov/pubmed/18886031
Mephenesin is a centrally acting muscle relaxant. This medication is prescribed for muscle spasm. It can be used as an antidote for strychnine poisoning. Most common side effects are: lassitude, drowsiness, weakness, loss of appetite, nausea and vomiting, hypersensitivity reactions. Its clinical usefulness is considered to be limited by its brief duration of action.
CNS Activity
Originator
Approval Year
Doses
Dose | Population | Adverse events |
---|---|---|
500 mg single, oral |
healthy, 25 years n = 1 Health Status: healthy Age Group: 25 years Sex: M Population Size: 1 Sources: |
Disc. AE: Anaphylactic shock... AEs leading to discontinuation/dose reduction: Anaphylactic shock Sources: |
7.5 g single, oral Overdose |
healthy, 48 years n = 1 Health Status: healthy Age Group: 48 years Sex: F Population Size: 1 Sources: |
Other AEs: Adverse event... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Anaphylactic shock | Disc. AE | 500 mg single, oral |
healthy, 25 years n = 1 Health Status: healthy Age Group: 25 years Sex: M Population Size: 1 Sources: |
Adverse event | grade 5 | 7.5 g single, oral Overdose |
healthy, 48 years n = 1 Health Status: healthy Age Group: 48 years Sex: F Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
DDT-induced tremor in rats: effects of pharmacological agents. | 1985 |
|
Analysis of neutral drugs in human plasma by fluoride attachment in liquid chromatography/negative ion electrospray tandem mass spectrometry. | 2004 |
|
Determination of guaifenesin in human serum by capillary gas chromatography and electron capture detection. | 2004 Jun 29 |
|
Descending respiratory polysynaptic inputs to cervical and thoracic motoneurons diminish during early postnatal maturation in rat spinal cord. | 2005 Feb |
|
Acupuncture therapy rapidly terminates intractable hiccups complicating acute myocardial infarction. | 2005 Mar |
|
Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs. | 2005 Sep-Oct |
|
Spinal ventral root after-discharges as a pain index: involvement of NK-1 and NMDA receptors. | 2006 Apr 12 |
|
Strategy for identification of leachables in packaged pharmaceutical liquid formulations. | 2008 Feb 13 |
|
Adverse drug effects in hospitalized elderly: data from the healthcare cost and utilization project. | 2010 |
|
Age estimation in 25-45 yrs. old females by physical and radiological methods. | 2010 Jul |
|
Permeability evaluation through chitosan membranes using taguchi design. | 2010 Oct-Dec |
Patents
Sample Use Guides
Oral: 1 to 2 tablets per dose (500 - 1000 mg), 3 times daily
Topical: 2 to 3 times a day with area messages of about ten minutes (duration - 5 days).
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14419235
Mephenesin is oxidatively metabolized in vitro 'by rat and mouse liver slices to 3- (o-tolyloxy)lactic acid. The uMoles of mephenesin metabolized per gram of fresh tissue was apparently a linear relationship with time up to 60 minutes. The maximum percent of substrate oxidized occurred between 1 500- 2000 ug.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:01:04 UTC 2023
by
admin
on
Fri Dec 15 15:01:04 UTC 2023
|
Record UNII |
7B8PIR2954
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
M03BX06
Created by
admin on Fri Dec 15 15:01:04 UTC 2023 , Edited by admin on Fri Dec 15 15:01:04 UTC 2023
|
||
|
WHO-VATC |
QM03BX06
Created by
admin on Fri Dec 15 15:01:04 UTC 2023 , Edited by admin on Fri Dec 15 15:01:04 UTC 2023
|
||
|
NCI_THESAURUS |
C29696
Created by
admin on Fri Dec 15 15:01:04 UTC 2023 , Edited by admin on Fri Dec 15 15:01:04 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
MEPHENESIN
Created by
admin on Fri Dec 15 15:01:04 UTC 2023 , Edited by admin on Fri Dec 15 15:01:04 UTC 2023
|
PRIMARY | |||
|
DTXSID4023254
Created by
admin on Fri Dec 15 15:01:04 UTC 2023 , Edited by admin on Fri Dec 15 15:01:04 UTC 2023
|
PRIMARY | |||
|
100000085372
Created by
admin on Fri Dec 15 15:01:04 UTC 2023 , Edited by admin on Fri Dec 15 15:01:04 UTC 2023
|
PRIMARY | |||
|
200-427-4
Created by
admin on Fri Dec 15 15:01:04 UTC 2023 , Edited by admin on Fri Dec 15 15:01:04 UTC 2023
|
PRIMARY | |||
|
m7187
Created by
admin on Fri Dec 15 15:01:04 UTC 2023 , Edited by admin on Fri Dec 15 15:01:04 UTC 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL229128
Created by
admin on Fri Dec 15 15:01:04 UTC 2023 , Edited by admin on Fri Dec 15 15:01:04 UTC 2023
|
PRIMARY | |||
|
59-47-2
Created by
admin on Fri Dec 15 15:01:04 UTC 2023 , Edited by admin on Fri Dec 15 15:01:04 UTC 2023
|
PRIMARY | |||
|
1691
Created by
admin on Fri Dec 15 15:01:04 UTC 2023 , Edited by admin on Fri Dec 15 15:01:04 UTC 2023
|
PRIMARY | |||
|
6755
Created by
admin on Fri Dec 15 15:01:04 UTC 2023 , Edited by admin on Fri Dec 15 15:01:04 UTC 2023
|
PRIMARY | RxNorm | ||
|
4059
Created by
admin on Fri Dec 15 15:01:04 UTC 2023 , Edited by admin on Fri Dec 15 15:01:04 UTC 2023
|
PRIMARY | |||
|
C76773
Created by
admin on Fri Dec 15 15:01:04 UTC 2023 , Edited by admin on Fri Dec 15 15:01:04 UTC 2023
|
PRIMARY | |||
|
D008615
Created by
admin on Fri Dec 15 15:01:04 UTC 2023 , Edited by admin on Fri Dec 15 15:01:04 UTC 2023
|
PRIMARY | |||
|
171
Created by
admin on Fri Dec 15 15:01:04 UTC 2023 , Edited by admin on Fri Dec 15 15:01:04 UTC 2023
|
PRIMARY | |||
|
25234
Created by
admin on Fri Dec 15 15:01:04 UTC 2023 , Edited by admin on Fri Dec 15 15:01:04 UTC 2023
|
PRIMARY | |||
|
DB13583
Created by
admin on Fri Dec 15 15:01:04 UTC 2023 , Edited by admin on Fri Dec 15 15:01:04 UTC 2023
|
PRIMARY | |||
|
SUB08746MIG
Created by
admin on Fri Dec 15 15:01:04 UTC 2023 , Edited by admin on Fri Dec 15 15:01:04 UTC 2023
|
PRIMARY | |||
|
94398
Created by
admin on Fri Dec 15 15:01:04 UTC 2023 , Edited by admin on Fri Dec 15 15:01:04 UTC 2023
|
PRIMARY | |||
|
7B8PIR2954
Created by
admin on Fri Dec 15 15:01:04 UTC 2023 , Edited by admin on Fri Dec 15 15:01:04 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |